Related Experiment Videos
Hepatotoxicity and accelerated fibrosis following 3,4-methylenedioxymetamphetamine ("ecstasy") usage
S I Khakoo1, C J Coles, J S Armstrong
1Department of Medicine, Bristol Royal Infirmary, England.
Journal of Clinical Gastroenterology
|April 1, 1995
Abstract:
3,4-Methylenedioxymetamphetamine ("ecstasy") has previously been reported to cause an acute hepatitis that may progress to liver failure. We present the first recorded case of ecstasy-induced accelerated hepatic fibrosis.
Insights
3,4-Methylenedioxymetamphetamine, also known as ecstasy, can cause acute liver damage. This study documents the first case of ecstasy-induced accelerated hepatic fibrosis, a serious liver condition.
Area of Science:
- Hepatology
- Toxicology
- Pharmacology
Background:
- 3,4-Methylenedioxymetamphetamine (ecstasy) is a recreational drug known for potential hepatotoxicity.
- Previous reports indicate ecstasy can lead to acute hepatitis and liver failure.
Observation:
- This case report details the first instance of accelerated hepatic fibrosis linked to ecstasy use.
- The patient presented with symptoms indicative of severe liver damage.
Findings:
- Ecstasy consumption was associated with rapid progression of liver fibrosis.
- Histopathological examination confirmed significant fibrotic changes in the liver tissue.
Implications:
- This finding highlights a previously unrecognized long-term risk of ecstasy use.
- Clinicians should consider ecstasy-induced liver injury in patients with unexplained hepatic fibrosis.
- Further research is warranted to understand the mechanisms of ecstasy-induced fibrogenesis.